MedDataX Logo

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

NCT04517838 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 230

Last updated 2025-12-24

No results posted yet for this study

Summary

This study gathers information from the blood cells and tumor tissue during treatment with anti-HER2 therapies, such as trastuzumab, pertuzumab, lapatinib, or neratinib, in patients with HER2 positive stage I-IV breast cancer who are scheduled to start anti-HER2 therapy. The information gained from this study may help researchers better understand the relation between cell response and anti-HER2 therapies.

Conditions

  • Breast Adenocarcinoma
  • HER2-Positive Breast Carcinoma
  • Anatomic Stage I Breast Cancer AJCC v8
  • Anatomic Stage II Breast Cancer AJCC v8
  • Anatomic Stage III Breast Cancer AJCC v8
  • Anatomic Stage IV Breast Cancer AJCC v8

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of blood and tumor tissue samples

Sponsors & Collaborators

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Saranya Chumsri, MD · Mayo Clinic

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-31
Primary Completion
2028-07-27
Completion
2028-07-27

Countries

  • United States

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04517838 on ClinicalTrials.gov